Comparative Pharmacology
Head-to-head clinical analysis: ARIDOL versus THYREL TRH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIDOL versus THYREL TRH.
ARIDOL vs THYREL TRH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aridol (mannitol) is an osmotic agent that, when inhaled, increases airway osmolarity, leading to release of mediators from mast cells and eosinophils, causing bronchoconstriction in susceptible individuals. It is used as a bronchial challenge test to assess airway hyperresponsiveness.
Synthetic thyrotropin-releasing hormone (TRH) that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary.
For bronchial challenge testing: inhaled dose of 5 mg (one vial) via nebulizer, single administration.
Adult: 500 mcg IV bolus over 15-30 seconds; may repeat once after 15-30 minutes if needed.
None Documented
None Documented
16.1 ± 8.5 minutes in healthy adults. Clinical context: Short half-life allows repeated provocative testing within 2–3 hours.
Terminal elimination half-life is approximately 5–6 minutes in healthy adults. This short half-life reflects rapid enzymatic degradation and renal clearance, requiring rapid intravenous administration for diagnostic thyroid stimulation.
Primarily renal excretion of unchanged mannitol. Approximately 80% of the administered dose is excreted unchanged in urine within 12 hours; minor biliary/fecal elimination (<5%).
Primarily renal excretion of intact TRH and metabolites (deamido-TRH and acid-TRH). Approximately 90% of administered radioactivity is recovered in urine within 24 hours. Biliary/fecal excretion accounts for less than 10%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent